Efficacy and safety of zinc and hyaluronic acid in male patients with ejaculate volume reduction: a prospective, randomized, placebo-controlled, comparative clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004369

Enrollment

Registered

2019-10-23

Start date

2020-01-21

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : ? Group 1: Zinc complex + hyaluronic acid placebo (12 weeks), 2 tablets each, total 4 tablets once a day after meals ? Group 2: Zinc placebo + hyaluronic acid complex (12 weeks),

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1.A male patient with a reduction in ejaculatory volume 2.Those who voluntarily agreed to participate in this study

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with diabetes 2. Patients diagnosed with prostate cancer 3. Patients with a history of prostate surgery 4. Patients who have been receiving testosterone replacement therapy (TRT) or who have been treated with TRT within 3 months prior to randomization 5. Patients who have experienced drug use, surgery, or procedure that the investigator has determined could affect the ejaculatory ability 6. Those who are difficult to follow up to 3 months after the start of the study

Design outcomes

Primary

Measure	Time frame
average of MSHQ-EjD-SF Q3 score (ejaculate volume) change	—

Secondary

Measure	Time frame
average of MSHQ-EjD-SF total score (Q1-Q3) change;average of MSHQ-EjD-SF Q4 score (bother/satisfaction) change;IIEF Q9 and Q10 (orgasmic function domain score);Serum testosterone change;adverse effect;laboratory test result	—

Countries

Korea, Republic of

Contacts

Public ContactDugeon Moon

Koera University Guro Hospital

uromoon@gmail.com+82-2-2626-3201

Outcome results